We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD

News   Oct 23, 2009

 
KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD
 
 
Advertisement
 

RELATED ARTICLES


Stopping "Cytokine Storms" May Reduce Severe COVID-19 Symptoms

News

A clinical trial in people with COVID-19 is testing a drug that may halt an overactive immune response known as "cytokine storms" before it ramps up.

READ MORE

Olaparib Approved as First Gene-targeted Medicine for Prostate Cancer

News

Olaparib is a precision medicine that works by selectively targeting and killing cancer cells with faulty DNA repair machinery. On May 19, 2020, the Food and Drug Administration (FDA) approved olaparib for adult patients with a specific type of prostate cancer .

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE